Long-term recurrence of nonmelanoma skin cancer after topical methylaminolevulinate photodynamic therapy in a dermato-oncology department

Cabete, Joana; Rafael, Margarida; Cravo, Mariana; Moura, Cecília; Sachse, Fernanda; Pecegueiro, Manuela

doi:10.1590/abd1806-4841.20154080

Cited by 21 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Photofrin was the first photosensitizer approved by FDA in 1995 and Photofrin‐mediated PDT is the most widely used for reducing obstruction and relieving symptoms in patients with obstructing esophageal cancer . In spite of promising initial treatment responses after PDT, 5‐year recurrence rate remains at high level . Consequently, improving the therapeutic efficacy of PDT is needed.…”

Section: Introductionmentioning

confidence: 99%

Enhanced phototoxicity of photodynamic treatment by Cx26‐composed GJIC via ROS‐, calcium‐ and lipid peroxide‐mediated pathways

Lin

Bai

et al. 2017

Journal of Biophotonics

View full text Add to dashboard Cite

In spite of the promising initial treatment responses presented by photodynamic therapy (PDT), 5-year recurrence rates remain high level. Therefore, improvement in the efficacy of PDT is needed. There are reports showing that connexin(Cx) 26-composed gap junctional intercellular communication (GJIC) enhances the intercellular propagation of "death signal", thereby increasing chemotherapeutic cytotoxicity. However, it is unclear whether Cx26-formed GJIC has an effect on PDT phototoxicity. The results in the present study showed that Cx26-composed GJ formation at high density enhances the phototoxicity of Photofrin-PDT. When the Cx26 is not expressed or Cx26 channels are blocked, the phototoxicity in high-density cultures substantially reduces, indicating that the enhanced PDT phototoxicity at high density is mediated by Cx26-composed GJIC. The GJIC-mediated increase in PDT phototoxicity was associated with ROS, calcium and lipid peroxide-mediated stress signaling pathways. The work presents the ability of Cx26-composed GJIC to enhance the sensitivity of malignant cells to PDT, and indicates that maintenance or increase of Cx26-formed GJIC may be a profitable strategy towards the enhancement of PDT therapeutic efficiency.Picture: The survival response of Photofrin-PDT in Doxtreated (Cx26 expressing, GJ-formed) and Dox-untreated cells (Cx26 non-expressing, GJ-unformed) at high-cell density condition.

show abstract

Section: Introductionmentioning

confidence: 99%

Enhanced phototoxicity of photodynamic treatment by Cx26‐composed GJIC via ROS‐, calcium‐ and lipid peroxide‐mediated pathways

Lin

Bai

et al. 2017

Journal of Biophotonics

View full text Add to dashboard Cite

show abstract

“…Local treatment, good cosmetic outcome, low normal tissue toxicity and ability to retreat if necessary make photodynamic therapy (PDT) very attractive for treatment of small solid tumours 1–4 . PDT’s mechanism of action is based on light activation of photosensitizer molecules and formation of singlet oxygen in conditions of good tissue blood supply and oxygenation 5 .…”

Section: Introductionmentioning

confidence: 99%

Accurate early prediction of tumour response to PDT using optical coherence angiography

Sirotkina

Moiseev

Matveev

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Prediction of tumour treatment response may play a crucial role in therapy selection and optimization of its delivery parameters. Here we use optical coherence angiography (OCA) as a minimally-invasive, label-free, real-time bioimaging method to visualize normal and pathological perfused vessels and monitor treatment response following vascular-targeted photodynamic therapy (PDT). Preclinical results are reported in a convenient experimental model (CT-26 colon tumour inoculated in murine ear), enabling controlled PDT and post-treatment OCA monitoring. To accurately predict long-term treatment outcome, a robust and simple microvascular metric is proposed. It is based on perfused vessels density (PVD) at t = 24 hours post PDT, calculated for both tumour and peri-tumour regions. Histological validation in the examined experimental cohort (n = 31 animals) enabled further insight into the excellent predictive power of the derived early-response OCA microvascular metric. The results underscore the key role of peri-tumour microvasculature in determining the long-term PDT response.

show abstract

“…Supporting this observation, Nissen and coworkers found that PDT was more effective in younger patients, and described an age-associated decrease in the formation of PpIX (4). Other authors have found no evidence of such an association (5,6).…”

Section: Discussionmentioning

confidence: 83%

Photodynamic Therapy: Influence of Clinical and Procedure Variables on Treatment Response in Basal Cell Carcinoma and Bowen Disease

Gracia‐Cazaña

Mascaraque²,

Salazar³

et al. 2018

Acta Derm Venerol

View full text Add to dashboard Cite

This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta Acta Derm Venereol 2018; 98: 116-118 116 Photodynamic therapy (PDT) is one of the most commonly used non-invasive treatments in non-melanoma skin cancer (NMSC). High rates of complete remission can be obtained using PDT with methyl-aminolevulinate (MAL); for basal cell carcinoma (BCC) the response rate is 91% at 3 months and 76% at 5 years, with 5-year recurrence rates of 22% in superficial BCC (sBCC) and 14% in nodular BCC (nBCC) (1, 2), and for Bowen disease (BD) the rate ranges from 88% to 100% at 3 months with 68% to 89% of treated lesions remaining clear for 17 to 50 months, besides PDT provides excellent cosmetic results and a high patient satisfaction rate (1-3).The primary limiting factors for MAL-PDT are pain during irradiation, tumoural thickness, tumour location (reduced sustained clearance rates for H-zone lesions), and certain histological features of BCCs such as pigmentary, morphoeaform, and infiltrative variants are considered contra-indications to treatment (3). Although the PDT procedure has changed little since its introduction, we conducted a retrospective analysis to evaluate how individual procedural variables relating to PDT influence the clinical response of BCC and BD. MATERIALS AND METHODSThis retrospective observational study analysed clinical and procedural variables for all cases of BD, nBCC and sBCC treated with MAL-PDT at San Jorge Hospital (Huesca, Spain) between January 2006 and December 2015.Patients were treated with MAL-PDT (Metvix ® , Galderma, La Defense Cedex, France) following the standard procedure (3). Patients with nBCC first underwent curettage debulking of the lesions. After applying haemostatic pressure, MAL was applied to the lesion and a surrounding area of 1 cm in diameter, and was incubated for 3 h under occlusion. The treated area was illuminated with a coherent monochromatic diode light source (630 nm, 37 J/ cm 2 , Aktilite ® , PhotoCure ASA, Norway).The clinical records of all patients were reviewed and data gathered for the following variables: age at onset, sex, phototype (Fitzpatrick scale I-IV), predisposing factors, location, size and type of tumour. The following procedural variables were considered: number of PDT sessions; fluorescence emitted by the lesion in response to a Wood's lamp; interruption of illumination due to pain; analgesia prior to irradiation and pain score as evaluated using a visual analogue scale (0-10). Clinical response was evaluated at the end of patient follow-up.Statistical analyses were performed using the statistical package SPSS, version 19.0 (IBM, Armonk, NY, USA). Associations between qualitative variables were assessed using the Pearson chi-squared test or Fisher exact test. The normal distribution of quantitative variables was evaluated using the Kolmogorov-Smirnov test. Depending on the data distribution, associations between binary and quantitative variables were evaluated using either the Student's t-test or Mann-Whitney U-test. In cas...

show abstract

Long-term recurrence of nonmelanoma skin cancer after topical methylaminolevulinate photodynamic therapy in a dermato-oncology department

Cited by 21 publications

References 22 publications

Enhanced phototoxicity of photodynamic treatment by Cx26‐composed GJIC via ROS‐, calcium‐ and lipid peroxide‐mediated pathways

Enhanced phototoxicity of photodynamic treatment by Cx26‐composed GJIC via ROS‐, calcium‐ and lipid peroxide‐mediated pathways

Accurate early prediction of tumour response to PDT using optical coherence angiography

Photodynamic Therapy: Influence of Clinical and Procedure Variables on Treatment Response in Basal Cell Carcinoma and Bowen Disease

Contact Info

Product

Resources

About